Fujimoto Chinatsu, Maruyama Yuji, Niina Yuusuke, Fujimori Nao, Sumii Toshihiko, Funakoshi Akihiro
Dept. of Gastroenterology, National Kyushu Cancer Center.
Gan To Kagaku Ryoho. 2008 Jun;35(6):1013-6.
The patient was a 70-year-old man with metastatic pancreatic cancer. After he received combination chemotherapy with gemcitabine and oral S-1 on day 1, he experienced severe general fatigue, anorexia and nausea. Then we changed the dose of gemcitabine from 1,000 mg/m(2) 2 to 500 mg/m(2) according to the criteria for an individual maximum repeatable dose (iMRD) determination method on day 8. His general condition recovered, and treatment schedule of gemcitabine with S-1 was continued sequentially at an outpatient clinic. His tumor marker levels, and the sizes of primary pancreatic tumor and liver metastatic lesions remarkably decreased. Partial response has been obtained for 7 months.
